Concord Biotech Limited
NSE: CONCORDBIOPharmaceuticals
Share price
₹1,330.80
-2.13% close of 8 Oct 2026
Business score
How strong the business is, in one number. The parts behind it are in Pro.
63
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹13,308 Cr
P/E ratio
47.7
P/B ratio
6.9
ROCE
17.1%
ROE
12.5%
Dividend yield
0.6%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales fell 6.7% over the past year. Meanwhile what it keeps of every 100 rupees of sales slipped from 38.2% to 34.9% over the last three years.
Whether it grew faster than its sector
It grew 8.6% a year against a sector median of 13.1% — 4.5 percentage points slower.
Room to re-rate, or risk of de-rating
At 47.7× earnings it costs 2.0× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 50.5×, the 36th percentile of its own range.
Whether growth justifies the valuation
Its earnings are falling, so growth cannot justify the price.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Concord Biotech Limited — this one | 0%/yr | 47.7× | — |
| Sun Pharmaceutical | 13%/yr | 33.4× | ₹2.6 |
| Divi's Laboratories | 13%/yr | 83.3× | ₹6.4 |
| Torrent Pharmaceuticals | 22%/yr | 78.7× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.1× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 98.6× | ₹24.7 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 49 of 130 on returns, 83 of 127 on growth, 12 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A narrow advantage: it earns 17.1% on capital, ahead of 62% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹1230 crore of cash from the business, spent ₹591 crore on plant and equipment, and returned ₹496 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 7 years, about 88 arrived as cash. Its cash comes back more slowly than it used to: it went from being waiting 161 days for its cash to waiting 230 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
8 of 9 checks clear · 89%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Revenue up 26% and profit up 31% from a year ago
Announced 31 Jul 2026 · Consolidated
Revenue
₹257 Cr
Revenue vs last year
+26.2%
Revenue vs last quarter
-21.0%
Net profit
₹58 Cr
Profit vs last year
+31.1%
Profit vs last quarter
-34.4%
Net margin
22.4%
EPS
₹5.52
Earnings call transcript · 3 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹13,308 Cr
- Prev close
- ₹1,330.80
- 52w High
- ₹1,627
- 52w Low
- ₹987
- Enterprise value
- ₹13,908 Cr
- Beta
- 0.8
- Price CAGR 1y
- -16.0%
- Price CAGR 3y
- 6.0%
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 11.6%
- PEG ratio
- —
- P/E ratio
- 47.7
- P/B ratio
- 6.9
- EV / EBITDA
- 37.8
- Industry P/E
- 38.0
- ROCE
- 17.1%
- ROCE 5y average
- 24.0%
- ROE
- 12.5%
- Debt / Equity
- 0.0
- Interest coverage
- 346.0
- Dividend yield
- 0.6%
- ROE 3y average
- 18.0%
- ROE last year
- 12.0%
Annual P&L
- Annual revenue
- ₹1,055 Cr
- Annual profit
- ₹259 Cr
- Operating margin
- 35.0%
- Net profit margin
- 24.5%
- EBITDA margin
- 34.9%
- Sales growth 3y
- 7.3%
- Sales growth 5y
- 11.4%
- Profit growth 3y
- 0.0%
- Profit growth 5y
- 1.0%
- EPS
- ₹24.9
- Sales growth TTM
- -7.0%
- Profit growth TTM
- -22.0%
- Dividend payout
- 30.0%
Quarter P&L
- Sales latest quarter
- ₹257 Cr
- Profit latest quarter
- ₹58 Cr
- YoY quarterly sales growth
- 26.2%
- YoY quarterly profit growth
- 31.8%
- OPM latest quarter
- 32.0%
Balance Sheet
- Book Value
- ₹202
- Face Value
- ₹1.0
- Total debt
- ₹2 Cr
- Total cash
- ₹14 Cr
- Borrowings
- ₹2 Cr
- Reserves / Equity
- 200.7
Cash Flow
- Operating cash flow
- ₹267 Cr
- Free cash flow
- ₹172 Cr
- FCF yield
- 1.3%
- Net cash flow
- ₹11 Cr
Shareholding
- Promoter holding
- 44.1%
- FII holding
- 7.5%
- DII holding
- 9.4%
- Public holding
- 39.0%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,781.00 | 33.8 | 4,27,322 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,588.00 | 85.4 | 2,54,531 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,716.20 | 80.4 | 1,79,389 | 0.81 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,153.00 | 23.6 | 1,15,012 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,052.80 | 101.4 | 1,10,915 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,327.20 | 30.0 | 1,07,221 | 0.98 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Mankind Pharma | 2,500.00 | 48.4 | 1,03,261 | 0.04 | 574.1 | 29.6 | 4,030.6 | 12.9 | 13.5 |
| Concord Biotech | 1,359.70 | 51.2 | 14,225 | 0.56 | 57.7 | 32.8 | 257.5 | 26.2 | 17.1 |
| Median | 417.90 | 34.5 | 2,208 | 0.07 | 13.5 | 29.5 | 164.0 | 18.4 | 15.0 |
Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Symbiotec Pharmalab Limited, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 |
| Expenses | 123 | 147 | 135 | 187 | 135 | 176 | 146 | 241 | 143 | 159 | 179 | 208 | 175 |
| Material Cost | 80 | 60 | 57 | 67 | 71 | 70 | |||||||
| Change in Inventories | 38 | -28 | -22 | -21 | -0.40 | -27 | |||||||
| Purchases of Stock-in-Trade | 10 | 13 | 14 | 20 | 16 | 11 | |||||||
| Employee Cost | 39 | 38 | 44 | 47 | 48 | 44 | |||||||
| Other Expenses | 72 | 60 | 65 | 66 | 74 | 77 | |||||||
| Operating Profit | 72 | 116 | 106 | 132 | 81 | 134 | 98 | 189 | 61 | 88 | 98 | 118 | 82 |
| OPM % | 37 | 44 | 44 | 41 | 38 | 43 | 40 | 44 | 30 | 36 | 35 | 36 | 32 |
| Other Income | 13 | 8 | 11 | 11 | 12 | 10 | 17 | 9 | 15 | 16 | 7 | 15 | 14 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | -3.28 | 0 | 0 | |||||||
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 20 | 18 |
| Profit before tax | 71 | 110 | 103 | 129 | 80 | 130 | 101 | 184 | 59 | 86 | 86 | 114 | 78 |
| Tax % | 23 | 26 | 25 | 26 | 25 | 27 | 25 | 24 | 25 | 26 | 26 | 22 | 26 |
| Net Profit | 54 | 81 | 78 | 95 | 60 | 96 | 76 | 140 | 44 | 63 | 64 | 88 | 58 |
| EPS in Rs | 5.21 | 7.74 | 7.41 | 9.08 | 5.70 | 9.15 | 7.26 | 13 | 4.21 | 6.08 | 6.16 | 8.49 | 5.59 |
| Diluted EPS in Rs | 13 | 4.21 | 6.03 | 6.08 | 8.46 | 5.52 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 512 | 616 | 713 | 853 | 1,017 | 1,200 | 1,055 | 1,108 |
| Expenses | 308 | 289 | 443 | 509 | 585 | 694 | 687 | 721 |
| Material Cost | 264 | 254 | ||||||
| Change in Inventories | -15 | -71 | ||||||
| Purchases of Stock-in-Trade | 56 | 63 | ||||||
| Employee Cost | 139 | 177 | ||||||
| Other Expenses | 249 | 265 | ||||||
| Operating Profit | 205 | 327 | 270 | 344 | 432 | 506 | 368 | 388 |
| OPM % | 40 | 53 | 38 | 40 | 42 | 42 | 35 | 35 |
| Other Income | 32 | 14 | 23 | 37 | 37 | 44 | 52 | 52 |
| Exceptional items (within Other Income) | 0 | -3.28 | ||||||
| Interest | 1 | 1 | 6 | 5 | 3 | 1 | 1 | 0 |
| Depreciation | 21 | 28 | 50 | 54 | 54 | 54 | 74 | 75 |
| Profit before tax | 214 | 313 | 238 | 322 | 413 | 495 | 345 | 364 |
| Tax % | 21 | 25 | 26 | 25 | 25 | 25 | 25 | |
| Net Profit | 169 | 235 | 175 | 240 | 308 | 372 | 259 | 273 |
| EPS in Rs | 178 | 247 | 184 | 23 | 29 | 36 | 25 | 26 |
| Diluted EPS in Rs | 36 | 25 | ||||||
| Dividend Payout % | 22 | 0 | 3 | 30 | 30 | 25 | 30 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- 11%
- 3 years
- 7%
- TTM
- -7%
Compounded profit growth
- 10 years
- —
- 5 years
- 1%
- 3 years
- 0%
- TTM
- -22%
Stock price CAGR
- 10 years
- —
- 5 years
- —
- 3 years
- 6%
- 1 year
- -16%
Return on equity
- 10 years
- —
- 5 years
- 18%
- 3 years
- 18%
- Last year
- 12%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 761 | 990 | 1,094 | 1,280 | 1,516 | 1,802 | 2,007 |
| Borrowings | 52 | 86 | 62 | 32 | 10 | 3 | 2 |
| Other Liabilities | 118 | 97 | 147 | 192 | 164 | 219 | 212 |
| Minority Interest | 0 | -1.92 | |||||
| Total Liabilities | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 |
| Fixed Assets | 240 | 546 | 573 | 593 | 575 | 795 | 789 |
| CWIP | 141 | 18 | 74 | 173 | 211 | 51 | 79 |
| Investments | 199 | 141 | 74 | 137 | 246 | 335 | 491 |
| Other Assets | 361 | 477 | 592 | 611 | 668 | 854 | 873 |
| Total Assets | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,235 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 155 | 167 | 207 | 246 | 265 | 245 | 267 |
| Cash from Investing Activity | -114 | -195 | -112 | -158 | -155 | -160 | -143 |
| Cash from Financing Activity | -43 | 31 | -100 | -85 | -99 | -99 | -113 |
| Net Cash Flow | -1 | 3 | -4 | 3 | 12 | -14 | 11 |
| Free Cash Flow | -1 | -38 | 52 | 101 | 180 | 134 | 172 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 131 | 105 | 119 | 117 | 125 | 159 | 159 |
| Inventory Days | 312 | 503 | 434 | 430 | 331 | 286 | 485 |
| Days Payable | 201 | 152 | 185 | 190 | 150 | 135 | 151 |
| Cash Conversion Cycle | 242 | 456 | 368 | 357 | 306 | 310 | 493 |
| Working Capital Days | 159 | 177 | 161 | 152 | 166 | 193 | 230 |
| ROCE % | 32 | 21 | 26 | 28 | 28 | 17 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
13.63cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
64,96,743inr
2026-03-31
News
News and filings about Concord Biotech Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- Fermentation substrate (dextrose/glucose/maltose sugars)
- Solvents (API purification/extraction)
Depends on the price of
- fuel
Sells to
- Glenmark Pharmaceuticals Limited · Fermentation-based immunosuppressant/oncology/anti-infective APIs (one of two largest cust…
- Global generic formulators (200+ customers across 70+ countries; long-term supply agreements) · Fermentation APIs + finished dosage formulations + CDMO
- Intas Pharmaceuticals · Fermentation-based APIs (one of two largest customers; Intas is unlisted)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE338H01029
Plants
- Unit 1 API Manufacturing Facility (Dholka)
- Unit 2 Formulation Facility · Valthera, Gujarat
- Unit 3 API Manufacturing Facility · Limbasi, Gujarat
- Unit 4 Injectable Facility · Valthera, Gujarat
News impact
Big market events that reach Concord Biotech Limited, and how the effect spreads.
12 Jun, 04:31 IST · Market event · medium impact
Concord Biotech gets USFDA nod — fermentation API pipeline boost
Who it hits first
- Concord Biotech receives USFDA approval
Who may gain
- CONCORDBIO
Along the supply chain
Downstream
US generic formulators gain visibility on Concord supply
Upstream
No direct supply-chain link — regulatory event
Where demand moves
Business
No supply-chain demand flow — corporate regulatory clearance affecting Concord-specific US-bound fermentation API exports.
Capital
Niche pharma rotation; Concord absorbs incremental flow.
How it spreads across sectors
Pharma APIs
CONCORDBIO outperforms; sector neutral
When it plays out
Immediate
3-5% pop
Medium term
Pipeline visibility
Short term
US revenue trajectory improves
Other sectors it reaches
- {"causal_chain":"USFDA approval boosts API exporter narrative","direction":"positive","example_tickers":["DIVISLAB","LAURUSLABS","SYNGENE"],"magnitude":"small","notes":"No L5.5 ran (single-sector MEDIUM event below trigger)","sector":"Pharma APIs","time_horizon":"immediate"}
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 24 Jul 2026 | unspecified | ₹7.55 |
|---|---|---|
| 3 Sep 2025 | unspecified | ₹10.7 |
| 21 Jun 2024 | unspecified | ₹8.75 |
Splits, bonuses & buybacks
- daily-prices repair: 8 rows from NSE's archive (replace 2, delete 1, insert 5), 2023-11-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Nov 2023
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY273 Aug 2026
- Annual report · 2025-267 Jul 2026
- Results presentation30 Jun 2026
- Earnings call · Q4FY261 Jun 2026
- Earnings call · Q3FY2612 Feb 2026
- Earnings call · Q2FY2614 Nov 2025
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.